Natural products targeting human lactate dehydrogenases for cancer therapy: A mini review

Huankai Yao1*, Feng Yang2 and Yan Li1

1Department of Microbial and Biochemical Pharmacy, School of Pharmacy, Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China, 2School of Stomatology, Xuzhou Medical University, Xuzhou, Jiangsu, China

Reorienting cancer metabolism has become the hallmark of cancer progress. As the key enzyme catalyzing the conversion of pyruvate to lactate in aerobic glycolysis of cancer cells, human lactate dehydrogenase (LDH) has been a promising target in the discovery of anticancer agents. Natural products are important sources of new drugs. Up to now, some natural compounds have been reported with the activity to target LDH. To give more information on the development of LDH inhibitors and application of natural products, herein, we reviewed the natural compounds with inhibition of LDH from diverse structures and discussed the future direction of the discovery of natural LDH inhibitors for cancer therapy.

KEYWORDS
natural products, lactate dehydrogenase, cancer metabolism, Warburg effect, inhibitors

Introduction

In recent years, metabolic reprogramming has attracted more attention regarding cancer progression, as cancer cells have a distinct metabolism compared to normal cells (Hay, 2016). In normal cells, the glucose is transported into cytosol by glucose transporters (GLUT) and converted into pyruvate under the catalysis of a series of enzymes. The latter will enter into the mitochondria and degrade to form acetyl-CoA catalyzed by pyruvate dehydrogenase complex (PDC) to generate more ATP if there is enough of an oxygen source, which is called oxidative phosphorylation (OXPHOS). Under hypoxic conditions, the pyruvate will be converted to lactate under the catalysis of lactate dehydrogenase (LDH) following the oxidation of NADH to NAD+ as anaerobic glycolysis (Cairns et al., 2011). However, in cancer cells, the high amounts of glucose are taken up to produce more ATP and meet the requirements of cellular proliferation. Meanwhile, most lactate is produced when enough oxygen is available (Figure 1A). This phenomenon is usually termed as aerobic glycolysis or the Warburg effect (Vander Heiden et al., 2009).

Of all the enzymes in cancer metabolism, LDH is a key node of aerobic glycolysis since this pathway affords the conversion of about 85% pyruvate to lactate (Figure 1B) (Zhang et al., 2015). In many cancer cells, such as gastric cancer (Ping et al., 2018), colorectal cancer (Wang et al., 2015), lung cancer (Kayser et al., 2010), liver cancer (Faloppi et al., 2016),
breast cancer (Arundhathi et al., 2021), brain cancer (Valvona et al., 2016), bladder cancer (Burns et al., 2021) and so on, it was found that LDH has been expressed excessively. LDH is closely associated with the diagnosis, treatment, and prognosis of cancer patients as it is involved in all stages of cancer progression. Targeting LDH not only inhibits the proliferation, tumorigenesis, and progression, but also suppresses the invasion, metastasis, and angiogenesis of cancer (Feng et al., 2018). Therefore, inhibiting LDH to target cancer metabolism is a potential therapeutic approach to discover anticancer agents (Zhang et al., 2018; Stine et al., 2022).

As the NADH-dependent enzyme, lactate dehydrogenase is a tetramer composed of two major subunits, LDHA (also known as LDH-M) and LDHB (also known as LDH-H), which are encoded by LDHA and LDHB genes, respectively (Markert et al., 1975). Therefore, according to the number of different subunits, there are five isoforms of LDH, named LDH1-LDH5 (Figure 1C)(Dawson et al., 1964). The metabolic characteristics of LDH isoforms are determined by the composition of subunits. LDHA preferentially reduces pyruvate to lactate while LDHB kinetically favors the conversion of lactate to pyruvate (Echigoya et al., 2009; Augoff et al., 2015). Hence, LDHA or LDH5 often attracts medicinal chemists’ attention as the target to regulate cancer metabolism (Rani and Kumar, 2017; Zhang et al., 2018). In addition, there are some other isoforms of LDH including LDHC, LDHD, and LDHBx. LDHC, also known as LDHX, is testes-specific (Blanco and Zinkham, 1963; Burkhart et al., 1982). Until now, the role of LDHD has been less understood, and it is reported that LDHD is responsible for the metabolism of D-lactate in vivo (Monroe et al., 2019). LDHBx localized in the peroxisome and is generated by translational readthrough (Schueren et al., 2014).

In the discovery of new drugs, natural products play a pivotal role (Newman and Cragg, 2020). To find novel LDH inhibitors, some natural compounds have been explored (Figure 2) that showed structural and pharmacological diversity. Herein we summarize these compounds to give insights into the future discovery of LDH inhibitors.

Natural compounds as lactate dehydrogenase inhibitors

Terpenoids

Terpenoids are a class of hydrocarbon compounds derived from isoprenoids and classified based on the number of...
FIGURE 2
Natural products with potential inhibition of LDH.
isoprenoid moieties. In the screening of LDH inhibitors, some terpenoids showed significant potential. Panepoxone, a monoterpenoid identified from *Lentinus strigellus*, reduced oxygen consumption, lactate production, and ATP synthesis in breast cancer cells via inhibiting LDHA (Arora et al., 2015). Ursolic acid is a ursane-type triterpenoid found in many plants and offers some pharmacological effects. Recently, it was found that ursolic acid at 500 μM inhibited LDHA with the inhibition rate of 30.5% ± 6.7% by electrophoretically mediating microanalysis (Li et al., 2021). Using the ultrafiltration-high speed countercurrent chromatography technique, dehydropachymic acid, pachymic acid, dehydrotrametenolic acid, trametenolic acid, and eburicoic acid from *Poria cocos* were identified as LDH inhibitors as well as lanosterol together with betulin from *Inonotus Obliquus* (Li et al., 2017a; Wang et al., 2021), and most of those are rich in higher fungus such as lanostane-type triterpenoids.

**Alkaloids**

Alkaloids are natural compounds containing nitrogen atoms and the secondary metabolites synthesized from amino acids. The first alkaloid as an LDHA inhibitor is berberine. As the major isoquinoline-type alkaloid in *Coptis chinensis*, berberine offers the significant inhibitory constant of 12.6 μM and dissociation constant of 3.1 μM while interacting with LDHA (Kapp and Whiteley, 1991). Further investigation has revealed berberine suppressed progression of pancreatic adenocarcinoma through functionally inhibiting LDHA (Cheng et al., 2021). Additionally, through the visual screening from the NCI Diversity Set, the microbial secondary metabolite lomofungin was selected as an LDH inhibitor as well as lanosterol together with betulin from *Inonotus Obliquus* (Li et al., 2017a; Wang et al., 2021), and most of those are rich in higher fungus such as lanostane-type triterpenoids.

**Flavonoids**

Flavonoids are the derivatives of chromones and contribute largely to the discovery of natural LDH inhibitors. As the flavanol analogue, galloflavon inhibited LDHA by virtual screening and was validated with the IC<sub>100</sub> of 201 μM. It was also observed that galloflavon inhibited ATP production in hepatocarcinoma PLC/PRF/5 cells as well as cell growth and respiration (Manerba et al., 2012). Galloflavon can occupy the NADH binding site of LDHA to prevent its binding to single stranded DNA and repress the proliferation of human colorectal cancer SW620 cells (Fiume et al., 2013). Meanwhile, galloflavon inhibited growth of various breast cancer cells via suppressing the proliferation and inducing oxidative stress resulting from blocking ATP production and glycolysis (Farabegoli et al., 2012). In Burkitt lymphoma cells, inhibiting LDHA by galloflavon caused MYC down-regulation, which is the most important survival signal (Vetraino et al., 2013). Similarly, urolithin M6, the galloflavon mimetic identified from gut microbiota metabolites, inhibited purified human LDHA with the IC<sub>50</sub> of 77 ± 10 μM as well as lactate production in Raji cells (IC<sub>50</sub> of 36 ± 3 μM) and cell growth (IC<sub>50</sub> of 25 ± 2 μM) (Rupiani et al., 2016). As the major flavanol in green tea, (-)-epigallocatechin gallate inhibits LDHA in MIA PaCa-2 pancreatic cancer cells and confers the anti-cancer activity by disrupting the cellular metabolic network (Ju et al., 2015). And its precursor, (-)-epigallocatechin, as an LDHA inhibitor could significantly inhibit breast cancer growth and induce apoptosis (Wang et al., 2013). In addition, luteolin-7-O-β-D-glucoside was reported to inhibit human LDH5 with the IC<sub>50</sub> of 139.2 ± 3.1 μM (Bader et al., 2015). And nortangeretin was found to inhibit LDHA with the IC<sub>100</sub> of 270 μM (Manerba et al., 2012). In the screening of phytochemicals, many flavonoids have been indicated with the potential to inhibit LDH such as quercetin, luteolin, tectoridin, iristectorin A, iridin, tectorigenin, irigenin, irisflorentin, acetyldaidzin, malonylgenestin, daidzin, glycitin, genistin, acetylglucitcin, daidzein, and tectorigenin-7-O-xylosylglucoside (Li et al., 2016; Tang et al., 2016; Li et al., 2021).

**Polyphenols**

In addition to flavonoids, there are other polyphenols with inhibitory effects on LDH. (R)-(−)-gossypol in cotton processes potent LDH inhibition. However, due to the high toxicity in the heart, kidney, and muscle, its application is hampered and it is hard to further develop it as an anticancer agent (Gomez et al., 1997). 3,6′-Di-O-sinapoylsucrose is a dimer of phenylpropiolic acid glucosides obtained from *Polygala flavesens* ssp. *flavesens*. It can inhibit human LDH5 with the IC<sub>50</sub> of 90.4 ± 4.4 μM through binding to the NADH binding site (De Leo et al., 2017). In addition to 3,6′-di-O-sinapoylsucrose, sibiricose A5, glomeratose A, tenuifoliside B, and tenuifoliside C were also screened as LDH inhibitors from Polygala tenuifolia (Li et al., 2017b). As the dimer of vanillin, vanililin inhibited LDHA with the IC<sub>100</sub> of 205 μM as well (Manerba et al., 2012). 1,2,3,4,6-Penta-O-galloylglucoside is a tannin occurring in *Galla Chinensis*, which could competitively bind to the NADH binding site of LDHA and inhibit its activity with IC<sub>50</sub> of 27.32 nM. It was also observed in human breast cancer MDA-MB-231 cells that this compound could block lactate production (IC<sub>50</sub> = 97.81 μM) and cell division (IC<sub>50</sub> = 1.2 μM) (Deiab et al., 2015).
Fatty acids

4-Hydroxy-2-nonenal is an α,β-unsaturated aldehyde, which is generated from the oxidation of n-6 linoleic acid and arachidonic acid. And enzyme activity oxidation assay uncovered that it inhibited LDH via covalent binding and reduced NADH formation (Ramanathan et al., 2014). Crocetin is a carotenoid found in medicinal plant saffron; its sodium salt could inhibit human LDH5 with the IC50 of 54.9 ± 4.7 μM and the proliferation of glycolytic cancer cell lines including human lung cancer A549 cells (IC50 = 114.0 ± 8.0 μM) and human cervical cancer HeLa cells (IC50 = 113.0 ± 11.1 μM) (Granchi et al., 2017).

Conclusion and perspective

As more attention is paid to metabolism reprogramming of cancer cells, the importance of the discovery of LDH inhibitors has been raised again. Natural products provide rich resources to find new LDH inhibitors. However, the present status is despondent and some challenges have to be encountered. The first is the work screening natural LDH inhibitors is poor, though the number of natural compounds is large, which may be overcome as more people pursue this avenue and the mature assay methods are employed. Meanwhile, the crystal structure of LDH has been established, which could give more insights into the affinity of natural compounds. The second is weak potency of natural products with a poor drug-like property, which should be improved by medicinal chemists through chemical synthesis. The last is the pharmacological evaluation and exploration of these natural compounds are insufficient and cannot provide sound evidence, especially in vivo, which may result from the small amounts obtained from nature. These compounds need to be enriched via both synthesis and isolation. In the future, the involvement of pharmacologists together with natural product chemists in the work will enhance those investigations. Collectively, the discovery of LDH inhibitors from natural products is still an attractive approach for cancer therapy, which should integrate multiple disciplines including natural products chemistry, medicinal chemistry, and pharmacology.

Author contributions

HY wrote the manuscript. FY and YL collected references. All the authors approve this manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Adams, M. J., McPherson, A., Jr., Rossmann, M. G., Schevitz, R. W., and Wonacott, A. J. (1970). The structure of the nicotinamide-adenine dinucleotide coenzyme when bound to lactate dehydrogenase. J. Mol. Biol. 51, 31–38. doi:10.1016/0022-2836(70)90267-6

Arora, R., Schmitt, D., Karanam, B., Tan, M., Yates, C., and Dean-Colomb, W. (2015). Inhibition of the Warburg effect with a natural compound reveals a novel measurement for determining the metastatic potential of breast cancers. Oncotarget 6, 662–678. doi:10.18632/oncotarget.2689

Arundhati, J. R. D., Mathur, S. R., Gogia, A., Deo, S. V. S., Mohapatra, P., and Prasad, C. P. (2021). Metabolic changes in triple negative breast cancer-focus on aerobic glycolysis. Mol. Biol. Rep. 48, 4733–4745. doi:10.1007/s11033-021-06414-w

Augoff, K., Hryniewicz-Iankowska, A., and Tabola, R. (2015). Lactate dehydrogenase 3: An old friend and a new hope in the war on cancer. Cancer Lett. 358, 1–7. doi:10.1016/j.canlet.2014.12.035

Bader, A., Tuccinardi, T., Granchi, C., Martinelli, A., Macchia, M., Minutolo, F., et al. (2015). Phenylpropanoids and flavonoids from Pholmis kurdica as inhibitors of human lactate dehydrogenase. Phytochemistry 116, 262–268. doi:10.1016/j.phytochem.2015.03.007

Blanco, A., and Zinkham, W. H. (1963). Lactate dehydrogenases in human testes. Science 139, 601–602. doi:10.1126/science.139.3555.601

Burkhart, J. G., Ansari, A. A., and Malling, H. V. (1982). Localization of cytoplasmic lactate dehydrogenase-X in spermatocytes. Arch. Androl. 9, 115–120. doi:10.3109/01485018208990228

Cairns, R. A., Harris, J. S., and Mak, T. W. (2011). Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85–95. doi:10.1038/nrc2981

Cheng, C. S., Tan, H. Y., Wang, N., Chen, L., Meng, Z., Chen, Z., et al. (2021). Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression. Clin. Transl. Med. 11, e467. doi:10.1002/ctm2.467

Cui, Y., Hu, X., Huang, X., Zhang, J., Zhang, Y., Zhu, W., et al. (2022). Inhibition of the Warburg effect with a natural compound reveals a novel measurement for determining the metastatic potential of breast cancers. Oncotarget 6, 662–678. doi:10.18632/oncotarget.2689

Deiab, S., Mazzio, E., Eyunni, S., McTier, O., Mateeva, N., Elshami, F., et al. (2015). Phenylpropanoids and flavonoids from Pholmis kurdica as inhibitors of human lactate dehydrogenase. J. Nat. Prod. 80, 2077–2087. doi:10.1021/acs.jnatprod.7b00295

Deleo, M., Talu, L. R., and Kaplan, N. O. (1964). Lactic dehydrogenases: Functions of the two types. Rates of synthesis of the two major forms can be correlated with metabolic differentiation. Science 143, 929–933. doi:10.1126/science.143.3609.929

Dawson, D. M., Goodfriend, T. L., and Kaplan, N. O. (1964). Lactic dehydrogenases: Functions of the two types. Rates of synthesis of the two major forms can be correlated with metabolic differentiation. Science 143, 929–933. doi:10.1126/science.143.3609.929

Evidence-Based Complementary Altern. Med. 2015, 1–11. doi:10.1155/2015/276946

Fatuca, A. M., Badea, M., and Tuculescu, M. (2017). Constituents of Polygala flavescent ssp. flavescent s and their activity as inhibitors of human lactate dehydrogenase. J. Nat. Prod. 80, 2077–2087. doi:10.1021/acs.jnatprod.7b00295

Huang, X., Cui, Y., Zhang, Y., Wang, N., et al. (2022). Inhibition of the Warburg effect with a natural compound reveals a novel measurement for determining the metastatic potential of breast cancers. Oncotarget 6, 662–678. doi:10.18632/oncotarget.2689

Huang, X., Cui, Y., Zhang, Y., Wang, N., et al. (2022). Inhibition of the Warburg effect with a natural compound reveals a novel measurement for determining the metastatic potential of breast cancers. Oncotarget 6, 662–678. doi:10.18632/oncotarget.2689

Mazzio, E., Eyunni, S., McTier, O., Mateeva, N., Elshami, F., et al. (2015). Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression. Clin. Transl. Med. 11, e467. doi:10.1002/ctm2.467

Mazzio, E., Eyunni, S., McTier, O., Mateeva, N., Elshami, F., et al. (2015). Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression. Clin. Transl. Med. 11, e467. doi:10.1002/ctm2.467

Prasad, C. P. (2021). Metabolic changes in triple negative breast cancer-focus on aerobic glycolysis. Mol. Biol. Rep. 48, 4733–4745. doi:10.1007/s11033-021-06414-w

Ramanathan, S., et al. (2017). Constituents of Polygala flavescent ssp. flavescent s and their activity as inhibitors of human lactate dehydrogenase. J. Nat. Prod. 80, 2077–2087. doi:10.1021/acs.jnatprod.7b00295

Wonacott, A. J. (1970). The structure of the nicotinamide-adenine dinucleotide coenzyme when bound to lactate dehydrogenase. J. Mol. Biol. 51, 31–38. doi:10.1016/0022-2836(70)90267-6

Yao et al. 10.3389/fchem.2022.1013670

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
and B genes. (2013). Gallo stranded DNA and inhibits RNA synthesis in cultured cells. Res. Commun. Mol. Biochem. 65, 5639–5649. doi:10.1016/S0079-7993(82)80131-9

Feng, Y., Xiong, Y., Qiao, T., Li, J., and Han, Y. (2018). Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy. Cancer Med. 7, 6124–6136. doi:10.1002/cam4.1820

Fiume, L., Vettriano, M., Manera, M., Fiume, L., Roberti, M., and Di Stefano, G. (2012). Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. Eur. J. Pharm. Sci. 47, 729–738. doi:10.1016/j.ejps.2012.08.012

Ping, W., Senyan, H., Li, G., Yan, C., and Long, L. (2018). Increased lactate in gastric cancer tumor-infiltrating lymphocytes is related to impaired T cell function due to miR-34a deregulated lactate dehydrogenase A. Cell. Physiol. Biochem. 49, 828–836. doi:10.1007/s00973-018-0836-7

Ramanathan, R., Mancini, R. A., Suman, S. P., and Beach, C. M. (2014). Covalent binding of 4-hydroxy-2-nonenal to lactate dehydrogenase decreases NADH formation and metmyoglobin reducing activity. J. Agric. Food Chem. 62, 2112–2117. doi:10.1021/jf404090y

Rani, R., and Kumar, V. (2017). When will small molecule lactate dehydrogenase inhibitors realize their potential in the cancer clinic? Future Med. Chem. 9, 1113–1115. doi:10.4155/fmc-2017-0082

Read, J. A., Winter, V. J., Ezes, C. M., Sessions, R. B., and Brady, R. L. (2001). Structural basis for altered activity of M- and H-isozyme forms of human lactate dehydrogenase. Proteins 43, 175–185. doi:10.1002/1056-8223(20010501)43:2<175::AID-PROT1029>3.0.CO;2-9

Rupiani, S., Guidotti, L., Manera, M., Di Ianni, L., Giacomini, E., Falchi, F., et al. (2016). Synthesis of natural urothiol M6, a galloflavin mimetic, as a potential inhibitor of lactate dehydrogenase A. Org. Biomol. Chem. 14, 19981–19987. doi:10.1039/c6ob01977c

Schueren, F., Lingner, T., George, R., Hofhuis, J., Dickel, C., Gartner, J., et al. (2014). Peroxosomal lactate dehydrogenase is generated by translational readthrough in mammals. Elife 3, e05460. doi:10.7554/eLife.05460

Stine, Z. E., Schug, Z. T., Salvino, J. M., and Deng, C. V. (2022). Targeting cancer metabolism in the era of precision oncology. Nat. Rev. Drug Discov. 21, 141–162. doi:10.1038/s41573-021-00399-6

Swidersk, K., Tunon, I., Marti, S., and Moliver, Y. (2015). Protein conformational landscapes and catalysis: influence of active site conformations in the reaction catalyzed by L-lactate dehydrogenase. ACS Catal. 5, 1172–1185. doi:10.1021/acscatal.0c00746

Tang, Y., Li, S., Li, S., Yang, X., Qin, Y., Zhang, Y., et al. (2016). Screening and isolation of potential lactate dehydrogenase inhibitors from five Chinese medicinal herbs: Soybean, Radix pueraria, Flos pueraria, Rhizoma belamcandae, and Radix astragali. J. Sep. Sci. 39, 2043–2049. doi:10.1002/jssc.201600050

Valvona, C. J., Fillmore, H. L., Nunn, P. B., and Pilkington, G. J. (2016). The regulation and function of lactate dehydrogenase A: Therapeutic potential in brain tumor. Brain Pathol. 26, 3–17. doi:10.1111/bpa.12299

Vander Heiden, M. G., Cantley, L. C., and Thompson, C. B. (2009). Understanding the Warburg effect. The metabolic requirements of cell proliferation. Science 324, 1029–1033. doi:10.1126/science.1168089

Vettriano, M., Manera, M., Govoni, M., and Di Stefano, G. (2013). Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1. Anticancer. Drugs 24, 862–870. doi:10.1097/CAD.0b013e32832836ea50

Wang, J., Wang, H., Liu, A., Fang, C., Hao, J., and Wang, Z. (2015). Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer. Oncotarget 6, 19456–19468. doi:10.18632/oncotarget.3318

Wang, Y., Guo, L., Liu, C., Zhang, Y., and Li, S. (2021). Total triterpenoid extract from Inonotus obliquus using ionic liquids and separation of potential lactate dehydrogenase Inhibitors realize their potential in the cancer clinic? Future Med. Chem. 13, 439–452. doi:10.4155/fmc-2019-028710.4155/fmc-2019-0287

Wang, Z., Wang, D., Han, S., Wang, N., Mo, F., Loo, T. Y., et al. (2013). Bioactivity-guided identification and cell signaling technology to delineate the lactate dehydrogenase A inhibition effects of Spaltholobus suberctus on breast cancer. PLoS One 8, e56631. doi:10.1371/journal.pone.0056631

Woodford, M. R., Chen, V. Z., Backe, S. J., Bratulavsky, G., and Mollapour, M. (2020). Structural and functional regulation of lactate dehydrogenase-A in cancer. Future Med. Chem. 12, 439–452. doi:10.4155/fmc-2019-028710.4155/fmc-2019-0287

Zhang, S. L., He, Y., and Tam, K. Y. (2018). Targeting cancer metabolism to develop human lactate dehydrogenase (hLDH) inhibitors. Drug Discov. Today 23, 1407–1415. doi:10.1016/j.drudis.2018.03.014

Zhang, W., Zhang, S. L., Hu, X., and Tam, K. Y. (2015). Targeting tumor metabolism for cancer treatment: Is pyruvate dehydrogenase kinase (PDK) a viable anticancer target? Int. J. Biol. Sci. 11, 1390–1400. doi:10.7150/ijbs.13325